Matrix metalloproteinases.

Matrix metalloproteinases (MMPs), also known as matrixins, belong to a group of zinc-dependent proteins, which are thought to play a central role in the breakdown of extracellular matrix. Collagen, elastin, gelatin and casein are major components cleaved by MMPs. The breakdown of these components is essential for many physiological processes such as embryonic development, morphogenesis, reproduction, and tissue resorption and remodelling. MMPs also participate in pathological processes such as arthritis, cancer, cardiovascular and neurological diseases. This review summarizes current knowledge regarding these proteins, their participation in physiological and pathophysiological roles, their involvement in activation and inhibition, and their interactions with other metal-binding proteins including metallothioneins.

[1]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Vojtech Adam,et al.  Vertebrate metallothioneins as target molecules for analytical techniques , 2010 .

[3]  F. Vizoso,et al.  Study of matrix metalloproteinases and their inhibitors in prostate cancer , 2010, British Journal of Cancer.

[4]  T. KiliÇ,et al.  Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations , 2010, Journal of Clinical Neuroscience.

[5]  M. Terol,et al.  VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. , 2010, Blood.

[6]  D. E. Machado,et al.  Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases , 2010, Journal of experimental & clinical cancer research : CR.

[7]  Jin-Ao Duan,et al.  Selective matrix metalloproteinase inhibitors for cancer. , 2009, Current medicinal chemistry.

[8]  Vojtech Adam,et al.  Metallothioneins and cancer. , 2009, Current protein & peptide science.

[9]  F. Fauvel-Lafève,et al.  Matrix metalloproteinases are involved in both type I (apoptosis) and type II (autophagy) cell death induced by sodium phenylacetate in MDA-MB-231 breast tumour cells. , 2009, Anticancer research.

[10]  Vojtech Adam,et al.  Effects of Reduced Glutathione, Surface Active Agents, and Ionic Strength on the Detection of Metallothioneins by Using of Brdicka Reaction , 2009 .

[11]  H. Nagase,et al.  Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.

[12]  P. Ascenzi,et al.  Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. , 2008, Current medicinal chemistry.

[13]  N. Farrell,et al.  Zinc metalloproteins as medicinal targets. , 2008, Chemical Society reviews.

[14]  M. Ittmann,et al.  Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. , 2008, Cancer Research.

[15]  A. Papatsoris,et al.  Matrix metalloproteinase inhibitors as anticancer agents. , 2008, The international journal of biochemistry & cell biology.

[16]  S. Matecki,et al.  L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. , 2008, The American journal of pathology.

[17]  D. Edwards,et al.  The regulation of matrix metalloproteinases and their inhibitors. , 2008, The international journal of biochemistry & cell biology.

[18]  Wenfang Xu,et al.  Progress in the development of matrix metalloproteinase inhibitors. , 2008, Current medicinal chemistry.

[19]  Xìao-chun Xu,et al.  Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer , 2008, International journal of cancer.

[20]  Vojtech Adam,et al.  An Electrochemical Detection of Metallothioneins at the Zeptomole Level in Nanolitre Volumes , 2008, Sensors.

[21]  Gillian Murphy,et al.  Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? , 2008, Nature Clinical Practice Rheumatology.

[22]  W. Maret,et al.  Thionein/metallothionein control Zn(II) availability and the activity of enzymes , 2008, JBIC Journal of Biological Inorganic Chemistry.

[23]  J. Raffetto,et al.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. , 2008, Biochemical pharmacology.

[24]  P. Papagerakis,et al.  Premature Stop Codon in MMP20 Causing Amelogenesis Imperfecta , 2008, Journal of dental research.

[25]  Zhiwei Wang,et al.  Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of notch-1 and nuclear factor-κB signaling , 2007 .

[26]  C. Brinckerhoff,et al.  Signal transduction and cell‐type specific regulation of matrix metalloproteinase gene expression: Can MMPs be good for you? , 2007, Journal of cellular physiology.

[27]  J. Kowalewski,et al.  Usefulness of MMP-9/TIMP-1 ratio in estimation of lung cancer invasion and metastasis , 2007 .

[28]  Jialiang Hu,et al.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.

[29]  Paula D. Bos,et al.  Mediators of vascular remodelling co-opted for sequential steps in lung metastasis , 2007, Nature.

[30]  D. Fishman,et al.  Torg Syndrome Is Caused by Inactivating Mutations in MMP2 and Is Allelic to NAO and Winchester Syndrome , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  T. Cawston,et al.  Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. , 2006, Best practice & research. Clinical rheumatology.

[32]  O. Schober,et al.  Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. , 2006, Current medicinal chemistry.

[33]  René Kizek,et al.  Attomole voltammetric determination of metallothionein , 2006 .

[34]  C. Overall,et al.  Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.

[35]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[36]  Jason L Johnson,et al.  Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. , 2005, Circulation research.

[37]  M. Ozdemir-Karatas,et al.  MMP20 Active-site Mutation in Hypomaturation Amelogenesis Imperfecta , 2005, Journal of dental research.

[38]  Jason L. Johnson,et al.  Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. López-Otín,et al.  MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO). , 2005, The Journal of clinical investigation.

[40]  Michael Sullivan,et al.  Metalloproteomics: high-throughput structural and functional annotation of proteins in structural genomics. , 2005, Structure.

[41]  Jian Cai,et al.  Metallothionein transfers zinc to mitochondrial aconitase through a direct interaction in mouse hearts. , 2005, Biochemical and biophysical research communications.

[42]  F. Mannello,et al.  Matrix metalloproteinase inhibitors as anticancer therapeutics. , 2005, Current cancer drug targets.

[43]  R. Ala-aho,et al.  Matrix metalloproteinases as therapeutic targets in cancer. , 2005, Current cancer drug targets.

[44]  A. Fourie,et al.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.

[45]  F. Spinale,et al.  Trafficking of the Membrane Type-1 Matrix Metalloproteinase in Ischemia and Reperfusion: Relation to Interstitial Membrane Type-1 Matrix Metalloproteinase Activity , 2005, Circulation.

[46]  V. Calcaterra,et al.  Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2 , 2005, Clinical genetics.

[47]  T. Hart,et al.  MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta , 2005, Journal of Medical Genetics.

[48]  Ping Wang,et al.  The Hemopexin Domain of Membrane-type Matrix Metalloproteinase-1 (MT1-MMP) Is Not Required for Its Activation of proMMP2 on Cell Surface but Is Essential for MT1-MMP-mediated Invasion in Three-dimensional Type I Collagen* , 2004, Journal of Biological Chemistry.

[49]  C. López-Otín,et al.  Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.

[50]  G. Parkin.  Synthetic Analogues Relevant to the Structure and Function of Zinc Enzymes , 2004 .

[51]  C. Clavel,et al.  Tumour invasion and matrix metalloproteinases. , 2004, Critical reviews in oncology/hematology.

[52]  Gerald Henkel,et al.  Metallothioneins: zinc, cadmium, mercury, and copper thiolates and selenolates mimicking protein active site features--structural aspects and biological implications. , 2004, Chemical reviews.

[53]  R. Khokha,et al.  Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development , 2003, British Journal of Cancer.

[54]  C. López-Otín,et al.  Loss of collagenase-2 confers increased skin tumor susceptibility to male mice , 2003, Nature Genetics.

[55]  Mina J. Bissell,et al.  Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis , 2003, The Journal of cell biology.

[56]  A. Takeshita,et al.  Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. , 2003, American journal of physiology. Heart and circulatory physiology.

[57]  G. Taraboletti,et al.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.

[58]  K. Osteen,et al.  The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. , 2003, Endocrine reviews.

[59]  S. Russell,et al.  Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases , 2003, Gene Therapy.

[60]  S. Weiss,et al.  Membrane Type I Matrix Metalloproteinase Usurps Tumor Growth Control Imposed by the Three-Dimensional Extracellular Matrix , 2003, Cell.

[61]  S. V. Van Doren,et al.  Global orientation of bound MMP-3 and N-TIMP-1 in solution via residual dipolar couplings. , 2003, Biochemistry.

[62]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[63]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[64]  Peter Friedl,et al.  Compensation mechanism in tumor cell migration , 2003, The Journal of cell biology.

[65]  William C. Parks,et al.  Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury , 2002, Cell.

[66]  M. Shibuya,et al.  MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.

[67]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[68]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[69]  I. Fidler,et al.  Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. , 2002, Journal of the National Cancer Institute.

[70]  V. Quesada,et al.  Structural and Enzymatic Characterization of Drosophila Dm2-MMP, a Membrane-bound Matrix Metalloproteinase with Tissue-specific Expression* , 2002, The Journal of Biological Chemistry.

[71]  W. Bao,et al.  Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. , 2002, Cardiovascular research.

[72]  K. Yoshizato,et al.  Interleukin-2-collagen chimeric protein which liberates interleukin-2 upon collagenolysis. , 2002, Protein engineering.

[73]  Judith Sylvester,et al.  Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[74]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[75]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[76]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[77]  Pauline M. Rudd,et al.  Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.

[78]  C. Brinckerhoff,et al.  Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors , 2001, Arthritis Research & Therapy.

[79]  R. Kizek,et al.  Determination of metallothionein at the femtomole level by constant current stripping chronopotentiometry. , 2001, Analytical chemistry.

[80]  K. Shirouzu,et al.  Imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 expression by tumor cells implicated in liver metastasis from colorectal carcinoma. , 2001, The Kurume medical journal.

[81]  M. Lafontan,et al.  Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. , 2001, Diabetes.

[82]  J. Foidart,et al.  Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. , 2001, Journal of cell science.

[83]  Oonagh Dowling,et al.  Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome , 2001, Nature Genetics.

[84]  A. Godzik,et al.  Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. , 2001, The Biochemical journal.

[85]  J W Smith,et al.  Substrate Hydrolysis by Matrix Metalloproteinase-9* , 2001, The Journal of Biological Chemistry.

[86]  S. Zucker,et al.  Imaging metalloproteinase activity in vivo , 2001, Nature Medicine.

[87]  M. Stack,et al.  Type I collagen stabilization of matrix metalloproteinase-2. , 2001, Archives of biochemistry and biophysics.

[88]  P. Tak,et al.  Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA , 2001, Annals of the rheumatic diseases.

[89]  L. Devy,et al.  MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  W. Parks,et al.  Epilysin, a Novel Human Matrix Metalloproteinase (MMP-28) Expressed in Testis and Keratinocytes and in Response to Injury* , 2001, The Journal of Biological Chemistry.

[91]  S. Tyagi,et al.  Tissue inhibitor of metalloproteinase‐4 instigates apoptosis in transformed cardiac fibroblasts , 2001, Journal of cellular biochemistry.

[92]  C. Sautès-Fridman,et al.  High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. , 2001, Cancer research.

[93]  Z. Werb,et al.  Stromelysin-1 Regulates Adipogenesis during Mammary Gland Involution , 2001, The Journal of cell biology.

[94]  J. Foidart,et al.  Down-Regulation of MT1-MMP Expression by the α3 Chain of Type IV Collagen Inhibits Bronchial Tumor Cell Line Invasion , 2001, Laboratory Investigation.

[95]  F. Spinale,et al.  Myocardial remodelling and matrix metallotxoteinases in heart failure: turmoil within the interstitium , 2001, Annals of medicine.

[96]  U. Felbor,et al.  Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.

[97]  S. Ye.  Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[98]  C. López-Otín,et al.  Dm1-MMP, a Matrix Metalloproteinase fromDrosophila with a Potential Role in Extracellular Matrix Remodeling during Neural Development* , 2000, The Journal of Biological Chemistry.

[99]  H. Birkedal‐Hansen,et al.  Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. , 2000, Cancer research.

[100]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[101]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[102]  D. Dinakarpandian,et al.  Identification of the 183RWTNNFREY191Region as a Critical Segment of Matrix Metalloproteinase 1 for the Expression of Collagenolytic Activity* , 2000, The Journal of Biological Chemistry.

[103]  Thiennu H. Vu,et al.  Matrix metalloproteinases: effectors of development and normal physiology. , 2000, Genes & development.

[104]  C. López-Otín,et al.  Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. , 2000, Cancer research.

[105]  S. Shapiro,et al.  Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. , 2000, The Journal of biological chemistry.

[106]  Z. Werb,et al.  The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.

[107]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[108]  R. Kalluri,et al.  Two RGD-independent αvβ3 Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties* , 2000, The Journal of Biological Chemistry.

[109]  P. D. Di Cesare,et al.  Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP) , 2000, FEBS letters.

[110]  H. Welgus,et al.  A versatile assay for gelatinases using succinylated gelatin. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[111]  N. Borkakoti.  Structural studies of matrix metalloproteinases , 2000, Journal of Molecular Medicine.

[112]  M. Polette,et al.  Modified Basement Membrane Composition During Bronchopulmonary Tumor Progression , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[113]  Bao Q. Pham,et al.  Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B* , 2000, The Journal of Biological Chemistry.

[114]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[115]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[116]  R. D. Dyer,et al.  Catalytic Activities and Substrate Specificity of the Human Membrane Type 4 Matrix Metalloproteinase Catalytic Domain* , 1999, The Journal of Biological Chemistry.

[117]  G I Murray,et al.  Matrix metalloproteinases in tumour invasion and metastasis , 1999, The Journal of pathology.

[118]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[119]  F. Cosset,et al.  Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors , 1999, Gene Therapy.

[120]  P. Carmeliet,et al.  Temporal and Topographic Matrix Metalloproteinase Expression after Vascular Injury in Mice , 1999, Thrombosis and Haemostasis.

[121]  Gurmit Singh,et al.  Transforming growth factor β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells , 1999, Clinical and Experimental Metastasis.

[122]  K. Nabeshima,et al.  Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. , 1999, The American journal of pathology.

[123]  R. Pierce,et al.  Matrix metalloproteinases generate angiostatin: effects on neovascularization. , 1998, Journal of immunology.

[124]  P. Koolwijk,et al.  A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[125]  U. Gilli,et al.  The role of neutrophil chemotactic cytokines in the pathogenesis of equine chronic obstructive pulmonary disease (COPD). , 1998, Veterinary immunology and immunopathology.

[126]  B. Caterson,et al.  Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the 'aggrecanase' and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan. , 1998, The Biochemical journal.

[127]  A. Hinek,et al.  Tropoelastin and Elastin Degradation Products Promote Proliferation of Human Astrocytoma Cell Lines , 1998, Journal of neuropathology and experimental neurology.

[128]  K. Wada,et al.  Cloning of three Caenorhabditis elegans genes potentially encoding novel matrix metalloproteinases. , 1998, Gene.

[129]  H. Emonard,et al.  Regulation of matrix metalloproteinase-2(gelatinase A, MMP-2), membrane-type matrixmetalloproteinase-1 (MT1-MMP) and tissue inhibitorof metalloproteinases-2 (TIMP-2) expression byelastin-derived peptides in human HT-1080 fibrosarcoma cell line , 1998, Clinical & Experimental Metastasis.

[130]  R. Klebe,et al.  Overview of matrix metalloproteinase expression in cultured human cells. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[131]  J. Westermarck,et al.  Enhancement of Fibroblast Collagenase (Matrix Metalloproteinase-1)Gene Expression by Ceramide Is Mediated by Extracellular Signal-regulated and Stress-activated Protein Kinase Pathways* , 1998, The Journal of Biological Chemistry.

[132]  L. Klotz,et al.  Central Role of Ferrous/Ferric Iron in the Ultraviolet B Irradiation-mediated Signaling Pathway Leading to Increased Interstitial Collagenase (Matrix-degrading Metalloprotease (MMP)-1) and Stromelysin-1 (MMP-3) mRNA Levels in Cultured Human Dermal Fibroblasts* , 1998, The Journal of Biological Chemistry.

[133]  M. Klagsbrun,et al.  Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* , 1997, The Journal of Biological Chemistry.

[134]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[135]  P. Carey,et al.  Matrix metalloproteinases , 1997, The British journal of surgery.

[136]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[137]  Hideaki,et al.  Effect of Metallothioneins on Collagenolytic Activity of Tumor Gelatinase B , 1997 .

[138]  J. Westermarck,et al.  Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors , 1997, Oncogene.

[139]  H. V. Van Wart,et al.  Hydrolysis of a Broad Spectrum of Extracellular Matrix Proteins by Human Macrophage Elastase* , 1997, The Journal of Biological Chemistry.

[140]  T. Wilkins,et al.  The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells , 1997, Infection and immunity.

[141]  I. Fidler,et al.  Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma , 1997, Cell.

[142]  Y. Okada,et al.  Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. , 1997, The Biochemical journal.

[143]  W. Lipscomb,et al.  Recent Advances in Zinc Enzymology , 1997 .

[144]  G. Murphy,et al.  Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[145]  C. Brinckerhoff,et al.  The AP-1 site and MMP gene regulation: what is all the fuss about? , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[146]  Y. Okada,et al.  Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules* , 1997, The Journal of Biological Chemistry.

[147]  E. Korzus,et al.  The Mitogen-activated Protein Kinase and JAK-STAT Signaling Pathways Are Required for an Oncostatin M-responsive Element-mediated Activation of Matrix Metalloproteinase 1 Gene Expression* , 1997, The Journal of Biological Chemistry.

[148]  C. López-Otín,et al.  The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. , 1996, Journal of molecular biology.

[149]  H. Nagase,et al.  Enhanced invasiveness of tumour cells after host exposure to heavy metals. , 1996, European journal of cancer.

[150]  H. Nagase,et al.  Effect of metallothioneins on transformation of gelatinase A from human fibroblast WI-38 cells. , 1996, Cancer letters.

[151]  Hideaki,et al.  Enhancing Effect of Metallothionein on Tumor Cell Invasion in vitro , 1996 .

[152]  R R Brentani,et al.  Collagen/collagenase interaction: Does the enzyme mimic the conformation of its own substrate? , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[153]  A. Newby,et al.  Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. , 1996, The Biochemical journal.

[154]  S. Spiegel,et al.  Signal transduction through lipid second messengers. , 1996, Current opinion in cell biology.

[155]  T L Blundell,et al.  X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. , 1996, Structure.

[156]  J. Voorhees,et al.  Molecular basis of sun-induced premature skin ageing and retinoid antagonism , 1996, Nature.

[157]  R. Giavazzi,et al.  Matrix metalloproteinase inhibition: a review of anti-tumour activity. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[158]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[159]  P. Petrides,et al.  Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. , 1995, Biological chemistry Hoppe-Seyler.

[160]  W. Bode,et al.  A helping hand for collagenases: the haemopexin-like domain. , 1995, Structure.

[161]  Jack P. Witty,et al.  Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. , 1995, Cancer research.

[162]  P. Chambon,et al.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[163]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[164]  J. Monboisse,et al.  The alpha 3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. , 1994, The Journal of biological chemistry.

[165]  W. Ruppitsch,et al.  Activity of ternary gelatinase A-TIMP-2-matrix metallo-proteinase complexes. , 1994, Biological chemistry Hoppe-Seyler.

[166]  A. Shinagawa,et al.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.

[167]  M. Seldin,et al.  Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP‐3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10 , 1994, Developmental dynamics : an official publication of the American Association of Anatomists.

[168]  M. Cockett,et al.  Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. , 1994, The Journal of biological chemistry.

[169]  A. Hanby,et al.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. , 1993, Cancer research.

[170]  G. Opdenakker,et al.  Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein , 1993, Journal of neuroscience research.

[171]  R Poulsom,et al.  Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. , 1992, The American journal of pathology.

[172]  J. O'Connell,et al.  The role of the C-terminal domain in collagenase and stromelysin specificity. , 1992, The Journal of biological chemistry.

[173]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[174]  R. Hembry,et al.  Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. , 1991, Journal of cell science.

[175]  W. Noack,et al.  The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. , 1991, European journal of biochemistry.

[176]  D. Auble,et al.  The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. , 1991, Biochemistry.

[177]  S. Shapiro,et al.  Human 92- and 72-kilodalton type IV collagenases are elastases. , 1991, The Journal of biological chemistry.

[178]  H. Birkedal‐Hansen,et al.  Sequence specificities of human fibroblast and neutrophil collagenases. , 1991, The Journal of biological chemistry.

[179]  B. Coulombe,et al.  Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. , 1991, Cancer research.

[180]  A Yasui,et al.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. , 1990, European journal of biochemistry.

[181]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-β by the proteoglycan decorin , 1990, Nature.

[182]  H. Birkedal‐Hansen,et al.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[183]  B. Fowler,et al.  Metal constitution of metallothionein influences inhibition of delta-aminolaevulinic acid dehydratase (porphobilinogen synthase) by lead. , 1987, The Biochemical journal.

[184]  D. Petering,et al.  Ligand substitution reactions of metallothioneins with EDTA and apo-carbonic anhydrase. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[185]  A. Eisen,et al.  Human skin collagenase. Isolation and mechanism of attack on the collagen molecule. , 1968, Biochimica et biophysica acta.

[186]  C. Lapière,et al.  Collagenolytic activity in amphibian tissues: a tissue culture assay. , 1962, Proceedings of the National Academy of Sciences of the United States of America.

[187]  F. Gomis-Rüth,et al.  Matrix metalloproteinases: fold and function of their catalytic domains. , 2010, Biochimica et biophysica acta.

[188]  A. Strongin.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. , 2010, Biochimica et biophysica acta.

[189]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[190]  R. Khokha,et al.  Unraveling metalloproteinase function in skeletal biology and disease using genetically altered mice. , 2010, Biochimica et biophysica acta.

[191]  A. Krüger,et al.  Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. , 2010, Biochimica et biophysica acta.

[192]  Seth M Cohen,et al.  To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. , 2010, Biochimica et biophysica acta.

[193]  D. Gingras,et al.  Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. , 2010, Biochimica et biophysica acta.

[194]  J. Quigley,et al.  Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. , 2010, Biochimica et biophysica acta.

[195]  I. Sagi,et al.  Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? , 2010, Biochimica et biophysica acta.

[196]  R. Kizek,et al.  Metallothionein--a promising tool for cancer diagnostics. , 2009, Bratislavske lekarske listy.

[197]  Antonio Rosato,et al.  Counting the zinc-proteins encoded in the human genome. , 2006, Journal of proteome research.

[198]  松村 紳一郎.  Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice , 2006 .

[199]  A. Newby,et al.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.

[200]  M. Brawer,et al.  Expression of metalloproteinase genes in human prostate cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[201]  L. Zentilin,et al.  AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo , 2004, Cancer Gene Therapy.

[202]  Carlos López-Otín,et al.  Matrix metalloproteinases and tumor progression. , 2003, Advances in experimental medicine and biology.

[203]  G. Salvesen,et al.  Proteases and the regulation of biological processes , 2003 .

[204]  K. Yamashita,et al.  Matrix Metalloproteinase 9 ( 92-kDa Gelatinase / Type IV Collagenase ) from HT 1080 Human Fibrosarcoma Cells , 2001 .

[205]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.

[206]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[207]  T. Ny,et al.  Regulation and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse ovary during gonadotropin-induced ovulation. , 1999, Endocrinology.

[208]  A. Kugler.  Matrix metalloproteinases and their inhibitors. , 1999, Anticancer research.

[209]  L. Matrisian,et al.  Matrix Metalloproteinases as Mediators of Reproductive Function , 2022 .

[210]  B. Olsen,et al.  A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[211]  G. Murphy,et al.  Activation of human neutrophil procollagenase by stromelysin 2. , 1996, European journal of biochemistry.

[212]  T. Sato,et al.  Tumor necrosis factor alpha (TNFalpha) induces pro-matrix metalloproteinase 9 production in human uterine cervical fibroblasts but interleukin 1alpha antagonizes the inductive effect of TNFalpha. , 1996, FEBS letters.

[213]  J. Quigley,et al.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. , 1995, The Journal of biological chemistry.

[214]  D J Prockop,et al.  Collagens: molecular biology, diseases, and potentials for therapy. , 1995, Annual review of biochemistry.

[215]  L. Liotta,et al.  Tumor cell interactions with the extracellular matrix during invasion and metastasis. , 1993, Annual review of cell biology.

[216]  K. Suzuki,et al.  Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). , 1991, Biomedica biochimica acta.

[217]  L. Matrisian,et al.  Expression and localization of the matrix metalloproteinase pump‐1 (MMP‐7) in human gastric and colon carcinomas , 1991, Molecular carcinogenesis.

[218]  H. Birkedal‐Hansen,et al.  Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[219]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.